scholarly journals The tranexamic acid: as chemical tourniquet during Ward-Mayo’s operation

Author(s):  
Sarbeswar Mandal ◽  
Sumanta Kumar Mondal ◽  
Pragati Awasthi Pathak ◽  
Kavita Agarwal

Background: The intra-operative blood loss which required transfusion is one of the complications in Ward-Mayo’s operation. The objective of this study was to evaluate its effectiveness to minimizes hemorrhage in Ward-Mayo’s operationMethods: It is a well-designed, Clinical, interventional, prospective, randomized control trial. In the department of obstetrics and gynecology, IPGMER-SSKM (PG) H, Kolkata, West Bengal, India. More than one-year study. After ethics approval, the total number of sixty-six cases will be selected with randomization for Ward-Mayo operation and allocated into two groups operated as - Gr-A (n = 33 cases) - by infiltrating locally tranexaminic acid, Gr-B (n = 33-controls) - application local conventional haemostatics.Results: The outcome informs of primary and secondary assessed, analyzed, tabulated and statistically significant showed accordingly as per graph pad software. In Table 1 and 2. The results of individual group (Gr. A and Gr. B) in forms of pry and Sec. outcomes showed that there are better outcomes in all aspects with zero mortality Tranexamic group than controls.Conclusions: This study concluded that the Tranexamic Acid can safely and effectively used by local infiltration during Ward-Mayo’ operation. Like other department, this technique can be utilized in other vaginal procedure (ex-Episiotomy).

2013 ◽  
Vol 149 (2_suppl) ◽  
pp. P188-P188 ◽  
Author(s):  
Anita Oh ◽  
Adam Luginbuhl ◽  
Joseph Curry ◽  
David M. Cognetti

2007 ◽  
Vol 63 (1) ◽  
pp. 57-61 ◽  
Author(s):  
Jana B. A. MacLeod ◽  
Jennifer Lefton ◽  
Doug Houghton ◽  
Christina Roland ◽  
James Doherty ◽  
...  

2017 ◽  
Vol 5 (3) ◽  
pp. 155-163 ◽  
Author(s):  
Shahinul Alam ◽  
SKM Nazmul Hasan ◽  
Golam Mustafa ◽  
Mahabubul Alam ◽  
Mohammad Kamal ◽  
...  

AbstractBackground and ObjectivesTo observe the effect of Pentoxifylline for 1 year on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis (NASH).Materials and MethodsA single center, open label Randomized Control Trial. Patients were included if they had ultrasonographic evidence of fatty liver and nonalcoholic fatty liver disease activity score (NAS) ≥ 5 on liver histology. A total of 35 patients were selected; 25 of PL (Experimental) group and 10 of L (Control) group. PL group received 400 mg pentoxifylline thrice daily along with lifestyle modification and there was only lifestyle modification for the L group. After one year, NAS and fibrosis was compared in both groups.ResultsIn PL group, NAS improved 2.10 ± 1.07; whereas in L group, NAS was 0.90 ± 0.99 (P = 0.006). As per the protocol analysis, NAS ≥ 2 improved in 15/20 (75%) in PL group and in 3/10 (30%) in L group (P = 0.018). In PL group, the individual component of NAS, steatosis improved from 2.30 ± 0.66 to 0.95 ± 0.76 (P = 0.000), lobular inflammation from 1.65 ± 0.59 to 1.05 ± 0.51 (P = 0.002) and hepatocyte ballooning from 1.50 ± 0.51 to 1.30 ± 0.57 (P = 0.258). In L group, steatosis improved from 2.30 ± 0.68 to 1.40 ± 1.08 (P = 0.01), lobular inflammation and hepatocyte ballooning did not improve. The fibrosis score did not improve in any group. In PL group, NAS improved significantly (P = 0.027; OR=22.76, CI=1.43-362.40) independent of weight reduction.ConclusionPentoxifylline for 1 year improves the hepatic histological activity but not fibrosis of NASH patients.


Sign in / Sign up

Export Citation Format

Share Document